We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Assembly Biosciences

News List

Assembly Biosciences to Wind-Down Microbiome Program americanpharmaceuticalreview
December 30, 2020
Assembly Biosciences will wind-down its microbiome program, enabling the company to prioritize resources and focus on the advancement of its pipeline of novel core inhibitors for chronic hepatitis B virus (HBV).
Extension Study of Vebicorvir for Chronic HBV Does Not Achieve Meaningful SVR Rates americanpharmaceuticalreview
November 16, 2020
Assembly Biosciences provided an update on the ongoing open-label Phase 2 extension study (Study 211) of vebicorvir (VBR, or ABI-H0731) in patients with chronic HBV infection. Study 211 is exploring whether sustained virologic response (SVR) could be ...
Assembly Biosciences Announces FDA Fast Track Designation for Chronic Hepatitis B Virus Treatment americanpharmaceuticalreview
July 21, 2020
Assembly Biosciences announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ABI-H2158 (2158) for the treatment of patients with chronic HBV infection.